Abstract
Background: The global rise in angina pectoris, a symptom of coronary artery disease, is primarily attributed to an aging population and increasing prevalence of comorbidities. This study aims to assess the efficacy and safety of Dazhu Hongjingtian injection (DZHJTI) as an adjunct treatment for both stable and unstable angina, thereby addressing a significant gap in current cardiac care research. Methods: This comprehensive study involves 2 parallel prospective cohorts across 28 medical centers in China, enrolling 1500 patients with stable angina and 2000 with unstable angina. Participants are randomized into 2 groups: one receiving the DZHJTI alongside standard therapy and the other receiving standard therapy alone. The study employs advanced statistical methods like Subgroup Analysis and Marginal Mean Weighting Through Stratification to analyze data accurately. Discussion: The primary outcome of this study is the reduction in the frequency of angina attacks posttreatment. Secondary outcomes include the evaluation of patient well-being through clinical measures such as nitrate dosage requirements, vital sign stability, electrocardiogram changes, and laboratory data. Patient-reported outcomes from targeted questionnaires will also be assessed to understand the impact on quality of life. The study’s results are expected to contribute significantly to the understanding of DZHJTI’s role in treating angina pectoris, potentially influencing future treatment guidelines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.